WHAT HUMAN AND ANIMAL RESEARCH FOUND
What Comparing the Tests Changes About Aging Claims
Which has more human testing? NAD+ has several treatment trials. MOTS-c mainly has animal experiments. The difference limits what you can conclude about strength, health, and claims about aging.
What has actually been tested in people
NAD+ research has several trials testing treatment in people. Trials gave substances that the body converts into NAD+. Blood levels rose, and some physical tests improved too. MOTS-c research hasn't tested treatment in a human trial. Animal improvements and patient blood findings answer different questions. The evidence therefore differs before any comparison of benefits begins.
Neither set of tests establishes an approved medicine for aging.
NAD+ and MOTS-c also do different jobs within cells. Comparing those jobs helps explain why scientists study both. The tests differ in subjects, ways of giving substances, and safety gaps. An experiment's method doesn't supply a treatment plan for you. No personal amount or schedule follows from the findings.
What the test results and safety gaps show
| What differs | NAD+ | MOTS-c |
|---|---|---|
| Substance and job | Cells make NAD+ for fuel supply and repairs. NR and NMN become NAD+ in the body. | MOTS-c is a 16-amino-acid peptide; proteins contain these same small parts. Energy-making cell parts produce MOTS-c. |
| What researchers measured | Blood NAD+, walking, muscle sugar use, and DNA repair work. | Muscle sugar use, movement, and energy supply in animal hearts. |
| People and animals tested | Human trials found raised blood NAD+. Lasting health gains remain limited [1][2][3]. | Studies mainly used mice and rats. Human risk-study count: 1, involving 94 patients receiving blood-filtering treatment [7]. |
| How the substance reached the body | People swallowed NMN or NR. Some clinics give pharmacy-made NAD+ through a vein [2][5]. | Animals received shots beneath skin or around organs deeper inside the belly. There is no tested human method [8]. |
| Approval and recalls | Supplements lack drug approval; FDA disputes NMN supplement sales. Pharmacy-made NAD+ had a Class I recall, the most serious level. | No human treatment approval; elite sport prohibits MOTS-c. |
| What remains unanswered | Raised blood NAD+ hasn't established lasting health improvements [1]. | No treatment trials establish human benefits, safety, or how added MOTS-c behaves inside people [8]. |
How the substances support different cell jobs
The two substances have different construction and different cell jobs. NAD+ has two linked chemical parts and changes form during energy production. Cells rely on that exchange when turning food into usable fuel. The same kind of work occurs throughout living things. MOTS-c has sixteen amino acids, pieces that also join into proteins. Its instructions occupy DNA within the energy-producing parts of a cell. Scientists thought those instructions made only RNA, which helps cells assemble proteins. Making MOTS-c showed that the same DNA can supply instructions for messages. MOTS-c instead carries messages toward DNA elsewhere inside the cell [11].
NAD+ supports fuel work; MOTS-c can change how other cell work proceeds.
What muscle sugar tests add beyond blood results
In women, NMN helped muscle respond more readily to insulin's effects [3]. Their blood sugar was above normal, but not high enough to be diabetes. Insulin is a hormone released into blood to help cells receive sugar. Better muscle response means muscle drew in sugar more readily. NAD+ also supports DNA repairs and energy supply. Aging and inflammation can increase how much NAD+ certain proteins spend [4].
MOTS-c muscle improvements mainly concern animals, leaving human treatment untested.
Animal researchers measured muscle sugar use and movement after giving MOTS-c. MOTS-c activates a protein that responds to the cell's fuel needs. Scientists also examine heart energy and messages within cells [6][9][11]. Further tests are still needed before benefits can be established for you.
What comparison groups can establish about treatment
NAD+ trials assigned people by chance to different treatment groups. People received substances that their bodies converted into NAD+. Blood NAD+ rose consistently during those trials. One trial also found better walking distance [2]. Another found improved muscle response to insulin [3]. Lasting protection against aging or disease still needs human testing.
No MOTS-c treatment trial with people supplies a matching comparison.
Mice given MOTS-c avoided diet-linked obesity and poor insulin response [11]. Movement improved in mice across different ages [9]. A rat study found heart changes in animals with diabetes [12]. Laboratory tests showed direct action on a protein controlling cell work [6]. Patient blood tests linked higher MOTS-c with greater later health risks [7]. Researchers followed patients rather than giving MOTS-c as a treatment. You can compare results only with that difference kept clear.
What swallowing and shots change about the risks
Human participants swallowed NMN or NR during the trials [2][3][5]. The body converts both substances into NAD+ after they are swallowed. Some clinics give pharmacy-made NAD+ through a vein instead. Giving NAD+ too quickly can cause discomfort. Contamination also prompted a recall of a pharmacy-made product [4].
A swallowed product and liquid through a vein have different risks.
Animals received MOTS-c shots beneath the skin or deeper inside the belly. The deeper shots entered the space around the organs, beneath the layer of muscle. No human trial has established a method, amount, or schedule. Studies haven't measured how added MOTS-c behaves inside people either [8]. An animal shot method therefore can't supply a treatment plan for you.
What drug approval and sport rules change
Supplement sales include NAD+ and substances the body converts into NAD+. Drug approval is missing, and FDA disputes NMN supplement sales [4]. Pharmacy-made NAD+ for shots or a vein also lacks FDA approval. Bacterial toxins prompted a Class I recall of at least one product. Class I means the most serious recall level [4]. WADA sports rules do not list NAD+-making substances as prohibited.
MOTS-c has no approved treatment use, and elite sport prohibits MOTS-c.
Laboratories receive MOTS-c for research, rather than as an approved supplement. Sports rules prohibit MOTS-c under peptide and energy-use groups [8]. Peptides contain small joined parts; proteins contain the same parts in larger groups. Athletes face those rules throughout the year. The laboratory label doesn't remove sports penalties or establish safety for your health.
What remains unproved about longer and healthier life
The most consistent NAD+ finding is raised blood levels. Lasting benefits for human health are much less clear. A 2025 review in Nature Metabolism gathered the human trial findings. Benefits remained limited, with little known about NAD+ changes in particular organs [1]. Blood results don't establish whether people age better or avoid disease.
MOTS-c still lacks the basic human trials needed to test treatment safety.
Neither human treatment trials nor measurements of added MOTS-c in people exist [8]. Animal improvements can give researchers reasons to plan further studies. Explanations of cell work can help form useful questions too. Those findings don't replace evidence of what happens to people receiving treatment. Your health depends on answers beyond a promising animal result.